Integration of electronic pathology reporting with clinical trial matching for advanced prostate cancer.


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
08 2021
Historique:
received: 25 08 2020
revised: 10 12 2020
accepted: 12 12 2020
pubmed: 10 1 2021
medline: 5 1 2022
entrez: 9 1 2021
Statut: ppublish

Résumé

Racial/ethnic diversity in prostate cancer (CaP) clinical trials (CTs) is essential to address CaP disparities. California Cancer Registry mandated electronic reporting (e-path) of structured data elements from pathologists diagnosing cancer thereby creating an opportunity to identify and approach patients rapidly. This study tested the utility of an online CT matching tool (called Trial Library) used in combination with e-path to improve matching of underrepresented CaP patients into CTs at time of diagnosis. This was a nonrandomized, single-arm feasibility study among patients with a new pathologic diagnosis of high-risk CaP (Gleason Score ≥8). Eligible patients were sent recruitment materials and enrolled patients were introduced to Trial Library. A total of 419 case listings were assessed. Patients were excluded due to physician contraindication, not meeting baseline eligibility, or unable to be reached. Final participants (N = 52) completed a baseline survey. Among study participants, 77% were White, 10% were Black/Hispanic/Missing, and 14% were Asian. The majority of the study participants were over 65 years of age (81%) and Medicare insured (62%). Additionally, 81% of participants reported using the Internet to learn about CaP. The majority (62%) of participants reported that Trial Library increased their interest in CT participation. The current study demonstrated that leveraging structured e-path data reporting to a population-based cancer registry to recruit men with high risk CaP to clinical research is feasible and acceptable. We observed that e-path may be linked with an online CT matching tool, Trial Library. Future studies will prioritize recruitment from reporting facilities that serve more racially/ethnically diverse patient populations.

Identifiants

pubmed: 33419644
pii: S1078-1439(20)30639-6
doi: 10.1016/j.urolonc.2020.12.010
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

494.e7-494.e14

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Hala T Borno (HT)

Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. Electronic address: Hala.borno@ucsf.edu.

Christine Duffy (C)

Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA; Greater Bay Area Cancer Registry, University of California San Francisco, San Francisco, CA.

Sylvia Zhang (S)

Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.

Alison J Canchola (AJ)

Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA; Greater Bay Area Cancer Registry, University of California San Francisco, San Francisco, CA.

Zinnia Loya (Z)

Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA.

Todd Golden (T)

Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA.

Debora L Oh (DL)

Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA; Greater Bay Area Cancer Registry, University of California San Francisco, San Francisco, CA.

Anobel Y Odisho (AY)

Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Department of Urology, University of California San Francisco, San Francisco, CA; Center for Digital Health Innovation, University of California, San Francisco, CA.

Scarlett Gomez (S)

Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA; Greater Bay Area Cancer Registry, University of California San Francisco, San Francisco, CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH